$DCOY

$1.10 +$0.07 (6.8%) Close

$DCOY Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Ownership

13F as of Q2 2026 · 655.2K shares outstanding

Who owns DCOY?

By type of holder

Institutions 0.7% Insiders 10.6% Everyone else 88.8%

Concentration Top 10 holders own 10.9%

Pierce Frederick II 5.3% · Rosenblum Mark J 1.7%

Institutional ownership

0.7%

+0.4 pts vs last qtr

Institutional holders

0 vs last qtr

Net shares bought

+2.7K

by institutions in Q2 2026

New / sold out

2 / 2

positions opened vs closed

How is ownership changing?

Institutions, last 8 quarters

Biggest buyers in Q2 2026

Vanguard Capital Management LLC NEW +4.0K
Caitong International Asset Management Co., Ltd NEW +2

Biggest sellers in Q2 2026

Tower Research Capital LLC (TRC) −765
UBS Group AG −521

Who is planning to sell?

No insider has filed a notice of proposed sale (Form 144) for Decoy Therapeutics Inc in the last 12 months.

Is your stake being diluted?

Diluted share count, FY2024–FY2025

+20.9%

+20.93% a year

Each share's claim on the business

−17.3%

shrank without buying or selling a share

Spent on buybacks vs paid in stock

— vs $493K

over 2 fiscal years

Diluted shares, split-adjusted

Buybacks Stock-based comp

How patient are the owners?

Institutional shares by how long they've been held

5+ years0% 3–5 years0% 1–3 years0% Under 1 year100%

Quarterly turnover

166.7%

of institutional shares changed hands

Top 10 managers, median time held

2 quarters

Super Investors

Investment managers reporting DCOY on Form 13F

Holder	Shares	% of company	Change vs last qtr	Held since	% of their book
VC Vanguard Capital Management LLC	4.0K	0.62%	NEW	Q2 '26	0.0%
Shares held by quarter Peak holding4.0K (Q2'26) Change over 8 quarters+4.0K Share of the company0.620% Vanguard Capital Management LLC's full portfolio →
TR Tower Research Capital LLC (TRC)	256	0.04%	−765 (−74.9%)	Q4 '25	0.0%
Shares held by quarter Peak holding4.4K (Q4'25) Change over 8 quarters+256 Share of the company0.040% Tower Research Capital LLC (TRC)'s full portfolio →

Vanguard Capital Management LLC

4.0K

% of company

0.62%

Change vs last qtr

NEW

Held since

Q2 '26

Tower Research Capital LLC (TRC)

256

% of company

0.04%

Change vs last qtr

−765 (−74.9%)

Held since

Q4 '25

4 more super investors behind a free account

See every manager holding Decoy Therapeutics Inc, how their position has changed, and how long they've held it.

Institutional Funds

Mutual funds and ETFs reporting DCOY on Form N-PORT; together they hold 1.9% of the company

Fund	Position value	Shares	% of company	% of the fund	As of
VE Vanguard Extended Market Index Fund Vanguard Index Funds	$29K	4.0K	0.62%	0.00%	June 30, 2026
FE Fidelity Extended Market Index Fund Fidelity Concord Street Trust	$23.2K	7.6K	1.16%	0.00%	August 31, 2026

Vanguard Extended Market Index Fund

Vanguard Index Funds

Position value

$29K

% of company

0.62%

% of the fund

0.00%

As of

June 30, 2026

Fidelity Extended Market Index Fund

Fidelity Concord Street Trust

Position value

$23.2K

% of company

1.16%

% of the fund

0.00%

As of

August 31, 2026

2 more funds behind a free account

See every fund holding Decoy Therapeutics Inc and how much of the fund the position is.

Insiders and 5%+ holders

From Forms 3/4/5 and Schedules 13D/G

Holder	Shares	% of company	Change vs last qtr	8 quarters	Held since	% of their book
PF Pierce Frederick II Insider	34.8K	5.32%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company5.320% Pierce Frederick II's insider activity →
RM Rosenblum Mark J Insider	11.4K	1.73%	—	—	—	—
Insider holdings come from Form 3/4/5 filings, which are not quarterly. Share of the company1.730% Rosenblum Mark J's insider activity →

Pierce Frederick II

Insider

34.8K

% of company

5.32%

Change vs last qtr

—

Held since

—

Rosenblum Mark J

Insider

11.4K

% of company

1.73%

Change vs last qtr

—

Held since

—

8 more holders behind a free account

See every insider and 5%+ holder of Decoy Therapeutics Inc.

Comments